Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligoamine compounds and derivatives thereof for cancer therapy

a technology of oligoamine compounds and derivatives, applied in the field of oligoamine compounds, can solve the problems of undesirable side effects of specific medicines, no effective treatment for other cancers,

Inactive Publication Date: 2009-02-17
PROGEN PHARMA INC
View PDF117 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite intensive research aimed at finding effective treatments for cancer, is well-known that, while some cancers can be treated with relative success, no effective treatments exist for other cancers.
While pharmaceutical treatments currently exist for microsporidiosis, such as albendazole and metronidazole (Flagyl), not all treatments are effective against every pathogen, and undesirable side effects to specific medicines can occur in certain individuals.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligoamine compounds and derivatives thereof for cancer therapy
  • Oligoamine compounds and derivatives thereof for cancer therapy
  • Oligoamine compounds and derivatives thereof for cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

examples

[0147]Chemical Synthesis Examples

[0148]The following examples are illustrative of the manufacture of several compounds according to the present invention, and are not intended to limit the invention disclosed and claimed herein in any fashion. The Examples are included herein solely to aid in a more complete understanding of the present invention.

[0149]All commercially available reagents were used without further purification. All reactions were followed by TLC (silica gel F264 precoated, Merck); column chromatography was carried out with silica gel (Merck 60, 0.040-0.063 mesh). The detection was performed either with UV light or the following reagents: KMnO4 soln. (1:1 mixture of 1% aq. KMnO4 soln. and 5% aq. Na2CO3 soln.); Schlittler reagent (iodine platinate) (1 g H2PtCl6 in 6 ml H2O, 20 ml 1N HCl and 25.5 g KI in 225 ml H2O diluted to 1 L) for amides and amines. IR measurements are presented in units of [cm−1] and were recorded on a Perkin-Elmer 781 instrument. NMR spectra were ...

example 1

[0150]

[0151]N-Boc-γ-Aminobutyric acid (1): (This compound can also be purchased commercially from Sigma-Aldrich Chemical Company, Saint Louis, Mo., USA, product B 1892). A solution of Boc2O (95 g, 435 mmol) in 600 ml of dioxane was added at 0° C. to a stirred mixture of NaHCO3 (73 g, 870 mmol) in H2O (500 ml) and γ-aminobutyric acid (30 g, 291 mmol), stirred for 1 h at 0° C. and for 10 h at 20° C. The reaction mixture was diluted with H2O (500 ml), extracted 3 times with CHCl3, the aqueous layer was acidified with 3% HCl to pH 7 and then with KHSO4 (20% aq. solution) to pH 2. The product was extracted 5 times with CHCl3, dried (Na2SO4) concentrated in vacuo, and crystallized from Et2O-petr. ether. Yield 54.05 g (97%). mp: 58-59° C. NMR (CDCl3): 1.44 (s, 9H), 1.83 (m, 2H), 2.40 (t, J=7.15, 2H), 3.10-3.30 (m, 2H), 4.7 (bs, 1H).

example 2

[0152]

[0153]1-Hydroxybenzotriazole derivative of N-Boc-γ-Aminobutyric acid (2): 1-Hydroxybenzotriazole (70.3 g, 520 mmol; abbreviated as “HOBt” as individual reagent and as “Bt” indicating ester) and dicyclohexylcarbodiimide (DCC, 107.41 g. 520 mmol) were added into an ice cold solution of the acid 1 (105.5 g, 519 mmol) in DMF (700 ml), the cooling bath was removed and the reaction mixture was stirred overnight at 20° C. DMF was evaporated in vacuo at 40° C., the residue was suspended in CH2Cl2 / H2O (2:1) mixture (1.5 liter), filtered, and the precipitate was washed with CH2Cl2 The washings and filtrate were combined, washed 4 times with H2O, washed with brine, dried (Na2SO4) and concentrated in vacuo. The product was re-precipitated from hot CH2Cl2 with Et2O. The mother liquor was concentrated and the residue was re-precipitated again from hot CH2Cl2 with Et2O. Both crops were combined, dried in vacuo to obtain 151 g (87% of 2 as a mixture of N- and O-isomers, which was used in the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 10 / 272,269, filed Oct. 16, 2002 now abandoned, which claims priority benefit of U.S. provisional patent application Ser. No. 60 / 329,982, filed Oct. 16, 2001. The entire contents of those applications are hereby incorporated herein by reference.STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH[0002]Not applicable.TECHNICAL FIELD[0003]This invention is directed to compounds and methods useful for treating cancer and other diseases caused by uncontrolled cell proliferation, and for treating microsporidiosis and other infectious diseases. More specifically, this invention is directed to oligoamine compounds which display anti-tumor activity in vitro and in vivo, and which display anti-microspora activity as well as methods of making and using those compounds.BACKGROUND ART[0004]Cancer is one of the leading causes of death in the world. According to the Wor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07C211/13A61K31/13A61K31/785A61K31/132A61P35/00C07B61/00C07C209/26C07C211/14C07C213/00C07C215/18C08G73/02
CPCC07C211/14C07C215/18A61P35/00
Inventor CLIFFORD, LEGAL REPRESENTATIVE, LINDAVALASINAS, ALDONIA L.BLOKHIN, ANDREI V.BASU, HIRAK S.MARTON, LAURENCE J.REDDY, VENODHAR K.FRYDMAN, BENJAMIN
Owner PROGEN PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com